RARA and acute promyelocytic leukemia: Treatment with ATRA, which targets the RA receptor and induces terminal differentiation of APL blasts, and ATO, which degrades the PML-RARα fusion protein and induces apoptosis, produce deep clinical responses, but are associated with DS, also known as the retinoic acid syndrome (RAS).